Tedizolid for treatment of acute bacterial skin and skin structure infections

References

• Benjamin AL, Gregory JM, Lena N, et al. A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes. BMC Infect Dis 2012;12:227
   PubMed Web of Science ®Google Scholar
• Sartelli M, Malangoni MA, May AK, et al. World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections. World J Emerg Surg 2014;9(1):57-75
   PubMedGoogle Scholar
• Stevens DL, Bisno AL, Chambers HF. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59(2):147-59
   PubMed Web of Science ®Google Scholar
• Das D, Tulkens PM, Mehra P, et al. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary. Clin Infect Dis 2014;58(S1):S51-7
   Google Scholar
• Talan DA, Krishnadasan A, Gorwitz RJ, et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 2011;53(2):144-9
   PubMed Web of Science ®Google Scholar
• Eckmann C, Dryden M. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res 2011;15(12):554-63
   Web of Science ®Google Scholar
• Stefani S, Chung DR, Lindsay JA, et al. Methicillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonization of typing methods. Int J Antimicrob Agents 2012;39(4):273-82
   PubMed Web of Science ®Google Scholar
• Jarvis WR, Jarvis AA, Chinn RY. National prevalence of methicillin resistant Staphylococcus aureus in inpatients at United States healthcare facilities, 2010. Am J Infect Control 2012;40(3):194-200
   PubMed Web of Science ®Google Scholar
• Dozois A, Thomsen I, Jimenez-Truque N, et al. Prevalence and molecular characteristics of methicillin-resistant Staphylococcus aureus among skin and soft tissue infections in an emergency department in Guyana. Emerg Med J 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Teh SH, Chi CY, Lin PC, et al. Management and outcome of adults with skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a tertiary hospital in central Taiwan. J Microbiol Immunol Infect 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Nathwani D, Eckmann C, Lawson W, et al. Influence of real-world characteristics on outcomes for patients with methicillin-resistant Staphylococcal skin and soft tissue infections: a multi-country medical chart review in Europe. BMC Infect Dis 2014;14:476
   PubMed Web of Science ®Google Scholar
• Zhao C, Liu Y, Zhao M, et al. Characterization of community acquired Staphylococcus aureus associated with skin and soft tissue infection in Beijing: high prevalence of PVL+ ST398. PLoS One 2012;7(6):e38577
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011;52(3):285-92
   PubMed Web of Science ®Google Scholar
• O’Brien DJ, Gould IM. Does vancomycin have a future in the treatment of skin infections? Curr Opin Infect Dis 2014;27(2):146-54
   PubMed Web of Science ®Google Scholar
• Shrestha NK, Mason P, Gordon SM. Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study. J Antimicrob Chemother 2014;69(5):1407-15
   PubMed Web of Science ®Google Scholar
• Mpenge MA, Mac Gowan AP. Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia. Ther Clin Risk Manag 2015;7(11):565-79
   Google Scholar
• Frampton JE. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. Drugs 2013;73(10):1067-94
   PubMed Web of Science ®Google Scholar
• Bassetti M, Nicolini L, Repetto E, et al. Tigecycline use in derious mosocomial infections: a drug use evaluation. BMC Infect Dis 2010;10:287
   PubMed Web of Science ®Google Scholar
• ZYVOX-Full prescribing information. Available from: http://labeling.pfizer.com/showlabeling.aspx?id=649 [Last accessed June 2015]
   Google Scholar
• Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis 2012;55(4):582-6
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358(9277):207-8
   PubMed Web of Science ®Google Scholar
• Gu B, Kelesidis T, Tsiodras S, et al. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 2013;68(1):4-11
   PubMed Web of Science ®Google Scholar
• O’Riordan W, Green S, Mehra P, et al. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary. Clin Infect Dis 2014;58(1):43-50
   Web of Science ®Google Scholar
• Locke JB, Finn J, Hilgers M, et al. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother 2010;54(12):5337-43
   PubMed Web of Science ®Google Scholar
• Morales G, Picazo J, Baos E, et al. Resistance tolinezolid is mediated by the CFR gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010;50(6):821-5
   PubMed Web of Science ®Google Scholar
• FDA. Tedizolid Phosphate [EB/OL]. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?CFID=37783639CFTOKEN=a72abd17b0823cd9-B3190C0C-A6D2-14A6-8B31F322C9580C41#apph-ist [Last accessed 20 June 2014]
   Google Scholar
• European Medicines Agency. Sivextro tedizolid. Available from: www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002846/WC500180896.pdf [Last accessed 22 January 2013]
   Google Scholar
• SIVEXTRO. Available from: www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2015_sivextro_173603-eng.php#a1 [Last accessed 17 January 2013]
   Google Scholar
• Shaw KJ, Poppe S, Schaadt R, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008;52(12):4442-7
   PubMed Web of Science ®Google Scholar
• Rodríguez-Avial I, Culebras E, Betriu C, et al. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother 2012;67(1):167-9
   PubMed Web of Science ®Google Scholar
• SIVEXTRO-Full prescribing information. Available from: http://sivextro.com/pdf/sivextro-prescribing-info.pdf [Last accessed March 2015]
   Google Scholar
• Kisgen JJ, Mansour H, Unger NR, Childs LM. Tedizolid: a new oxazolidinone antimicrobial. Am J Health Syst Pharm 2014;71(8):621-33
   PubMedGoogle Scholar
• Rybak JM, Roberts K. Tedizolid phosphate: a Next-Generation Oxazolidinone. Infect Dis Ther 2015; Epub ahead of print
   Google Scholar
• Brown SD, Traczewski MM. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother 2010;54(5):2063-9
   PubMed Web of Science ®Google Scholar
• Choi S, Im W, Bartizal K. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae. Antimicrob Agents Chemother 2012;56(9):4713-17
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for interpretation of MICs and zone diameters. Available from: www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_5.0_Breakpoint_Table_01.pdf [Last accessed 01 January 2015]
   Google Scholar
• Jones RN, Moet GJ, Sader HS, et al. TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. J Antimicrob Chemother 2009;63(4):716-20
   PubMed Web of Science ®Google Scholar
• Locke JB, Hilgers M, Shaw KJ. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother 2009;53(12):5265-74
   PubMed Web of Science ®Google Scholar
• Louie A, Liu W, Kulawy R, Drusano GL. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin- susceptible and methicillin-resistant Staphylococcus aureus in a mouse thigh infection model. Antimicrob Agents Chemother 2011;55(7):3453-60
   PubMed Web of Science ®Google Scholar
• Drusano GL, Liu W, Kulawy R, Louie A. Impact of granulocytes on the antimicrobial effect of Tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother 2011;55(11):5300-5
   PubMed Web of Science ®Google Scholar
• Flanagan SD, Bien PA, Munoz KA, et al. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy 2014;34(3):240-50
   PubMed Web of Science ®Google Scholar
• Flanagan S, Fang E, Muñoz KA, et al. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacotherapy 2014;34:891-900
   PubMed Web of Science ®Google Scholar
• Prokocimer P, Bien P, Surber J, et al. Phase 2, randomized, double-blind, dose- ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011;55(2):583-92
   PubMed Web of Science ®Google Scholar
• Ong V, Flanagan S, Fang E, et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos 2014;42(8):1275-84
   PubMed Web of Science ®Google Scholar
• Flanagan S, Passarell J, Lu Q, et al. Tedizolid population pharmacokinetics, exposure response, and target attainment. Antimicrob Agents Chemother 2014;58(11):6462-70
   PubMed Web of Science ®Google Scholar
• Flanagan S, Minassian SL, Morris D, et al. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother 2014;58(11):6471-6
   PubMed Web of Science ®Google Scholar
• Keel RA, Crandon JL, Nicolau DP. Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions. Antimicrob Agents Chemother 2012;56(6):3420-2
   PubMed Web of Science ®Google Scholar
• Lemaire S, Van Bambeke F, Appelbaum PC, Tulkens PM. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother 2009;64(5):1035-43
   PubMed Web of Science ®Google Scholar
• Prokocimer P, Bien P, Deanda C, et al. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2012;56(9):4608-13
   PubMed Web of Science ®Google Scholar
• Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolidfor treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013;309(6):559-69
   PubMed Web of Science ®Google Scholar
• Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections(ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2014;14(8):696-705
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. Available from: www.regulations.gov/#!-documentDetail;D=FDA-2010-D-0433-0002 [Last accessed 20 December 2013]
   Google Scholar
• European Medicines Agency. Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections. Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003417.pdf [Last accessed 17 January 2013]
   Google Scholar
• Shorr AF, Lodise TP, Corey GR, et al. Analysis of the phase3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2015;59(2):864-71
   PubMed Web of Science ®Google Scholar
• Bien P, Prokocimer P, Muñoz KA, Bohn J. The safety of multiple ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic Poster P1089. Proceedings of the 19th European Congress of Clinical Microbiology and Infectious Diseases. Helsinki, Finland, 2009
   Google Scholar
• Dreskin H, Muñoz KA, Fang E, et al. Safety and pharmacokinetics of single oral administration of tedizolid phosphate in healthy elderly subjects and adult control subjects Poster A-1293. Proceedings of the 52nd Inter science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 2012
   Google Scholar